Trend of Surgical Treatment of Localized Renal Cell Carcinoma.
Trend of Surgical Treatment of Localized Renal Cell Carcinoma. Perm J. 2019;23: Authors: Jabaji RB, Fischer H, Kern T, Chien GW Abstract INTRODUCTION: Rapid adoption of robotics has introduced a paradigm change in prostate cancer treatment, with more than 80% of prostatectomies performed robotically in 2015. For treatment of renal cell carcinoma (RCC), this change has not previously been reported. We evaluated trends in surgical management of RCC in Kaiser Permanente Southern California (KPSC) within the last 16 years, especially after adoption of robotics. METHODS: From January 1999 to September 2015, all KPSC members who underwent surgical treatment of suspected RCC were included retrospectively. Surgical approach, patient age, sex, clinicopathology, Charlson Comorbidity Index, and chronic kidney disease status were analyzed using robust Poisson multivariate regression. RESULTS: The study included 5237 patients. Partial nephrectomy was increasingly used during the study period, and its use surpassed radical nephrectomy in 2012. In a multivariate model, partial nephrectomy was associated with lower pathologic tumor stage (p
ConclusionsPBS gives good target coverage and local control while providing reductions in radiation dose to OARs for individuals who receive RT for HL compared with advanced photon RT. Our findings highlight groups of patients who would be expected to gain more dosimetric benefit from PBS. These findings facilitate the selection of patients who should be considered a priority for PT.
ConclusionsMinimally invasive management of B3 lesions (except ADH and PT) with VAB continues to be appropriate as an alternative to first-line OE in most cases, but with more frequent surveillance, especially for LN.
A new machine learning algorithm outperformed existing methods in differentiating benign nodules from cancer.Medscape Medical News
Date: Wednesday, 03 20, 2019; Speaker: Jehoshua Bruck, Professor, California Institute of Technology; Building 10; FAES Room 7
Date: Friday, 03 22, 2019; Speaker: Christine Campo Alewine, MD PhD, Investigator, NCI, NIH; Building 37, Rooms 6041 /6107 ; 6th floor conference room
Zongxin Ling, Li Shao, Xia Liu, Yiwen Cheng, Chongxian Yan, Ying Mei, Feng Ji, Xiaosun Liu
Publication date: Available online 18 March 2019Source: Stem Cell ResearchAuthor(s): Aditya S. Pawar, Alfonso Eirin, James D. Krier, John R. Woollard, Xiang-Yang Zhu, Amir Lerman, Andre J. van Wijnen, Lilach O. LermanAbstractIntroductionMesenchymal stem cells (MSCs) possess endogenous reparative properties and may serve as an exogenous therapeutic intervention in patients with chronic kidney disease. Cardiovascular risk factors clustering in the metabolic syndrome (MetS) might adversely affect cellular properties. To test the hypothesis that Mets interferes with MSC characteristics, we performed comprehensive comparison of...
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Whats Next With Aimwithimmunotherapy.org.For More Info Visit: Aimwithimmunotherapy.org Author: Cancer-News Added: 03/18/2019
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Benefits Of Aimwithimmunotherapy.org And The Various Resources It Provides For Patients And Physicians.For More Info Visit: Aimwithimmunot... Author: Cancer-News Added: 03/18/2019
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Assessment &Education Regarding (irAEs).For More Info Visit: Aimwithimmunotherapy.org Author: Cancer-News Added: 03/18/2019